antibody eef1a2  (Proteintech)

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: (a) Western blot of recombinant protein, protein extracts from the A549 cell line, and from normal human organs. reEF1A1 and reEF1A2 are recombinant proteins. Caption under organ name “1” and “2” mean two cases were examined for heart, lung and liver. (b) Western blot of A549 cells treated with si‐eEF1A2. Scrambled RNA was used for the negative control (NC). LUAD indicates lung adenocarcinoma tissues.

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques: Western Blot, Recombinant, Negative Control

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: Immunohistochemistry of eukaryotic elongation factor 1 alpha 2 (eEF1A2) in normal lung tissue and in lung adenocarcinoma. (a) Normal lung tissue. (b) Adenocarcinoma in situ. (c) Solid adenocarcinoma with eEF1A2 expression.

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques: Immunohistochemistry, In Situ, Expressing

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: Kaplan‐Meier curve of disease‐free survival of patients with eukaryotic elongation factor 1 alpha 2 (eEF1A2).

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques:

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: Univariate and multivariate analysis of adenocarcinoma ( n = 175) using the Cox proportional hazards model.

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques:

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: (a) Quantitative genomic PCR analysis of eukaryotic elongation factor 1 alpha 2 (eEF1A2) in lung adenocarcinoma. Five tumors immunohistochemically positive for eEF1A2 and two tumors immunohistochemically negative for eEF1A2 were subjected to the analysis. Each dot represents one tumor. A ratio (tumor/normal) of ≥1.5 was defined as representing gene amplification. (b) Fluorescence in situ hybridization of eEF1A2 in lung adenocarcinoma specimen. eEF1A2 amplification was detected in the tumor with increased expression of eEF1A2 DNA. Amplification of eEF1A2 was visualized as an increased number of red signals (eEF1A2) relative to green signals (Chromosome 20 centromeric probe: CEN20p).

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques: Amplification, Fluorescence, In Situ Hybridization, Expressing

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: Eukaryotic elongation factor 1 alpha 2 expression and clinicopathological features in patients with lung adenocarcinoma.

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques: Expressing, In Situ

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: (a) Western blot of recombinant protein, protein extracts from the A549 cell line, and from normal human organs. reEF1A1 and reEF1A2 are recombinant proteins. Caption under organ name “1” and “2” mean two cases were examined for heart, lung and liver. (b) Western blot of A549 cells treated with si‐eEF1A2. Scrambled RNA was used for the negative control (NC). LUAD indicates lung adenocarcinoma tissues.

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques: Western Blot, Recombinant, Negative Control

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: Immunohistochemistry of eukaryotic elongation factor 1 alpha 2 (eEF1A2) in normal lung tissue and in lung adenocarcinoma. (a) Normal lung tissue. (b) Adenocarcinoma in situ. (c) Solid adenocarcinoma with eEF1A2 expression.

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques: Immunohistochemistry, In Situ, Expressing

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: Kaplan‐Meier curve of disease‐free survival of patients with eukaryotic elongation factor 1 alpha 2 (eEF1A2).

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques:

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: Univariate and multivariate analysis of adenocarcinoma ( n = 175) using the Cox proportional hazards model.

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques:

Journal: Pathology International

Article Title: High expression of eukaryotic elongation factor 1‐alpha‐2 in lung adenocarcinoma is associated with poor prognosis

doi: 10.1111/pin.13457

Figure Lengend Snippet: (a) Quantitative genomic PCR analysis of eukaryotic elongation factor 1 alpha 2 (eEF1A2) in lung adenocarcinoma. Five tumors immunohistochemically positive for eEF1A2 and two tumors immunohistochemically negative for eEF1A2 were subjected to the analysis. Each dot represents one tumor. A ratio (tumor/normal) of ≥1.5 was defined as representing gene amplification. (b) Fluorescence in situ hybridization of eEF1A2 in lung adenocarcinoma specimen. eEF1A2 amplification was detected in the tumor with increased expression of eEF1A2 DNA. Amplification of eEF1A2 was visualized as an increased number of red signals (eEF1A2) relative to green signals (Chromosome 20 centromeric probe: CEN20p).

Article Snippet: To verify the specificity of the antibodies against eEF1A1 and eEF1A2, Western blotting was performed using monoclonal anti‐eEF1A1 antibody (ab157455; Abcam), polyclonal anti‐eEF1A2 antibody (GTX102326, GeneTex), and mouse monoclonal anti‐GAPDH antibody (sc‐32233, Santa Cruz Biotechnology). eEF1A1 and eEF1A2 recombinant proteins (Abnova) were used as positive controls.

Techniques: Amplification, Fluorescence, In Situ Hybridization, Expressing

Journal: Disease Models & Mechanisms

Article Title: Face-valid phenotypes in a mouse model of the most common mutation in EEF1A2 -related neurodevelopmental disorder

doi: 10.1242/dmm.050501

Figure Lengend Snippet: Eef1a expression analysis. (A,B) Mean Eef1a1 (A) and Eef1a2 (B) mRNA quantities in the brains of P24 mice in the E122K line, normalised to the geometric mean of Gapdh , Ubc and B2m transcript levels. Values for individual biological replicates are shown as dots. Genotypes were compared using ordinary one-way ANOVAs. There was no statistically significant difference in relative Eef1a1 mRNA quantities between genotypes [ F (2, 9)=0.2807, P =0.7616]. There was a statistically significant difference in relative Eef1a2 mRNA quantities between genotypes [ F (2, 9)=16.16, P =0.001]. *** P <0.001 (Dunnett's post-hoc test, +/+ versus other genotypes). (C) Representative Western blots of P24 brain, heart and muscle lysates showing eEF1A2 and a total protein stain. Brain lysates from wst/wst mice, homozygous for an Eef1a2 abolishing deletion , were used as a negative control for eEF1A2. Lysates from adult skeletal muscle were used as a positive control. Brightness and contrast settings were set separately for each blot shown for illustration purposes (applied to the whole image), but this did not affect the quantification using Image Studio Lite software. Western blots were performed in triplicate for each sex with values averaged across replicates. (D-I) Quantification of eEF1A2 levels, normalised to total protein and expressed as a percentage of wild-type expression levels, were compared using ordinary one-way ANOVAs. There were no statistically significant differences in relative eEF1A2 levels in male heart [E; F (2, 6)=1.595, P =0.2782] or female heart [H; F (2, 6)=1.949, P =0.2227]. There were statistically significant differences in relative eEF1A2 levels in male brain [D; F (2, 6)=13.32, P =0.0062], female brain [G; F (2, 6)=39.60, P =0.0003], male muscle [F; F (2, 6)=28.49, P =0.0009] and female muscle [I; F (2, 6)=39.76, P =0.0003]. ** P <0.01, *** P <0.001 (Dunnett's post-hoc test, +/+ versus other genotypes). Sample sizes are shown at the base of the bars. Error bars show the s.d. AU, arbitrary units.

Article Snippet: The custom rabbit anti-eEF1A2 primary antibody was manufactured to order by Proteintech (UK), and was equivalent to antibody eEF1A2-1 described by .

Techniques: Expressing, Western Blot, Staining, Negative Control, Positive Control, Software

Journal: Disease Models & Mechanisms

Article Title: Face-valid phenotypes in a mouse model of the most common mutation in EEF1A2 -related neurodevelopmental disorder

doi: 10.1242/dmm.050501

Figure Lengend Snippet: Eef1a expression analysis. (A,B) Mean Eef1a1 (A) and Eef1a2 (B) mRNA quantities in the brains of P24 mice in the E122K line, normalised to the geometric mean of Gapdh , Ubc and B2m transcript levels. Values for individual biological replicates are shown as dots. Genotypes were compared using ordinary one-way ANOVAs. There was no statistically significant difference in relative Eef1a1 mRNA quantities between genotypes [ F (2, 9)=0.2807, P =0.7616]. There was a statistically significant difference in relative Eef1a2 mRNA quantities between genotypes [ F (2, 9)=16.16, P =0.001]. *** P <0.001 (Dunnett's post-hoc test, +/+ versus other genotypes). (C) Representative Western blots of P24 brain, heart and muscle lysates showing eEF1A2 and a total protein stain. Brain lysates from wst/wst mice, homozygous for an Eef1a2 abolishing deletion , were used as a negative control for eEF1A2. Lysates from adult skeletal muscle were used as a positive control. Brightness and contrast settings were set separately for each blot shown for illustration purposes (applied to the whole image), but this did not affect the quantification using Image Studio Lite software. Western blots were performed in triplicate for each sex with values averaged across replicates. (D-I) Quantification of eEF1A2 levels, normalised to total protein and expressed as a percentage of wild-type expression levels, were compared using ordinary one-way ANOVAs. There were no statistically significant differences in relative eEF1A2 levels in male heart [E; F (2, 6)=1.595, P =0.2782] or female heart [H; F (2, 6)=1.949, P =0.2227]. There were statistically significant differences in relative eEF1A2 levels in male brain [D; F (2, 6)=13.32, P =0.0062], female brain [G; F (2, 6)=39.60, P =0.0003], male muscle [F; F (2, 6)=28.49, P =0.0009] and female muscle [I; F (2, 6)=39.76, P =0.0003]. ** P <0.01, *** P <0.001 (Dunnett's post-hoc test, +/+ versus other genotypes). Sample sizes are shown at the base of the bars. Error bars show the s.d. AU, arbitrary units.

Article Snippet: The custom rabbit anti-eEF1A2 primary antibody was manufactured to order by Proteintech (UK), and was equivalent to antibody eEF1A2-1 described by .

Techniques: Expressing, Western Blot, Staining, Negative Control, Positive Control, Software